News
  Date Title View
Sep 7, 2017
BURLINGTON, Mass., Sept. 07, 2017 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today will present results from an analysis that found patients treated in clinical trials of Zilretta™ (FX006), its lead candidate for the treatment of osteoarthritis (OA) knee pain, had a statistically significantly lower use o...
Aug 30, 2017
BURLINGTON, Mass., Aug. 30, 2017 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that Michael Clayman, M.D., President and Chief Executive Officer, will participate in an analyst-led fireside chat at the 2017 Wells Fargo Healthcare Conference on Wednesday, September 6, 2017 at 9:40am ET at the Westin...
Aug 8, 2017
Commercial preparations for the potential launch of ZilrettaTM (FX006) advancing rapidlyStudy evaluating the safety of repeat administration of Zilretta has been fully enrolledManagement strengthened with recent appointments of Mark Levine, General Counsel and Corporate Secretary an...
Aug 1, 2017
BURLINGTON, Mass., Aug. 01, 2017 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that it will host a conference call and webcast to provide an update on business operations and report its second-quarter 2017 financial results on Tuesday, August 8, 2017, at 4:30 p.m. ET. The dial-in numb...
Jul 10, 2017
Management to discuss the latest plans for the potential launch of ZilrettaTMClinical experts to share perspectives on ZilrettaCompany to introduce new pipeline candidate (FX101) BURLINGTON, Mass., July 10, 2017 (GLOBE NEWSWIRE) -- Flexio...
Jul 3, 2017
BURLINGTON, Mass., July 03, 2017 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that it will hold an Investor and Analyst Day on Monday, July 10, 2017. Flexion executives will discuss plans for commercializing Zilretta™ (FX006), the company's lead investigational product candidate for the tr...
Jun 28, 2017
BURLINGTON, Mass., June 28, 2017 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that it has further strengthened its leadership team with the appointment of Mark Levine as Senior Vice President, General Counsel and Secretary. Mr. Levine joins the company's impressive roster of industry veterans, and...
Jun 23, 2017
BURLINGTON, Mass., June 23, 2017 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that it has been recognized as one of the The Boston Business Journal's "Best Places to Work." Flexion ranked 5th in the medium business category (100 to 249 employees) and was presented with the awar...
Jun 10, 2017
BURLINGTON, Mass., June 10, 2017 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) will present the full results from a Phase 2 study which found its lead investigational product candidate Zilretta (also known as FX006) was associated with reduced blood glucose (BG) elevation compared with immediate release triamcinol...
May 22, 2017
Findings suggest Zilretta could potentially provide a cost-effective treatment option for patients with osteoarthritis of the knee BURLINGTON, Mass., May 22, 2017 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced the findings from a new health economics analysis of Zilr...
1
... NextLast
= add release to Briefcase